Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Liabilities and Shareholders Equity (2016 - 2021)

Phio Pharmaceuticals' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $27.9 million for Q3 2021.

  • For Q3 2021, Liabilities and Shareholders Equity rose 53.2% year-over-year to $27.9 million; the TTM value through Dec 2021 reached $93.5 million, up 36.44%, while the annual FY2020 figure was $15.7 million, 95.78% up from the prior year.
  • Liabilities and Shareholders Equity reached $27.9 million in Q3 2021 per PHIO's latest filing, down from $31.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $33.9 million in Q1 2021 to a low of $3.1 million in Q1 2018.
  • Average Liabilities and Shareholders Equity over 5 years is $13.8 million, with a median of $12.1 million recorded in 2019.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 70.61% in 2018, then soared 342.65% in 2019.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $4.1 million in 2017, then surged by 273.89% to $15.3 million in 2018, then crashed by 47.53% to $8.0 million in 2019, then surged by 95.78% to $15.7 million in 2020, then surged by 77.54% to $27.9 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Liabilities and Shareholders Equity are $27.9 million (Q3 2021), $31.7 million (Q2 2021), and $33.9 million (Q1 2021).